A Phase 2a Study of the Safety, Pharmacokinetics and Pharmacodynamics of STG-001 in Subjects With Stargardt Disease (STGD1) Caused by Autosomal Recessive Mutation in ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene
Latest Information Update: 02 Nov 2021
At a glance
- Drugs STG 001 (Primary)
- Indications Stargardt disease
- Focus Adverse reactions
- Sponsors Stargazer Pharmaceuticals
- 24 Apr 2021 Status changed from recruiting to completed.
- 15 Mar 2021 Planned End Date changed from 1 Mar 2021 to 30 Apr 2021.
- 15 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 31 Mar 2021.